StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant Pharma (VRX) EBITDA Guidance Just Above Maintenance Covenants - Evercore ISI's Raffat
June 7, 2016 8:06 AM
Evercore ISI analyst Umer Raffat notes that Valeant Pharma (NYSE: VRX) EBITDA guidance was bit ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Short Sales
Trader Talk
Next Articles
Valeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies
June 8, 2016 8:50 AM
Valeant (VRX) PT Cut to $33 at RBC Capital
June 8, 2016 7:07 AM
Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim
June 8, 2016 6:57 AM
Valeant (VRX) PT Cut to $38 at BMO Capital
June 8, 2016 6:27 AM
Valeant (VRX) Product Commentary 'Concerning', Piper Jaffray Says; PT Set at $19
June 7, 2016 11:44 AM
Valeant Pharma (VRX) Misses Q1 EPS by 10c; Cuts FY16 Outlook
June 7, 2016 6:02 AM
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM